scholarly journals Targeting the SHP2 phosphatase promotes vascular damage and inhibition of tumor growth

2020 ◽  
Author(s):  
Yuyi Wang ◽  
Ombretta Salvucci ◽  
Hidetaka Ohnuki ◽  
Andy D. Tran ◽  
Taekyu Ha ◽  
...  
Keyword(s):  
Endothelial Cells ◽  
Tumor Growth ◽  
Tyrosine Kinases ◽  
Vascular Endothelial Cells ◽  
Tyrosine Phosphatase ◽  
Tumor Hypoxia ◽  
Blood Perfusion ◽  
Tumor Vasculature ◽  
Immune Checkpoints ◽  
Tumor Vascularity

AbstractThe tyrosine phosphatase SHP2 is oncogenic in cancers driven by receptor-tyrosine-kinases, and SHP2 inhibition reduces tumor growth. Here, we report that SHP2 is an essential promoter of endothelial cell survival and growth in the remodeling tumor vasculature. Using genetic and chemical approaches to inhibit SHP2 activity in endothelial cells, we show that SHP2 inhibits pro-apoptotic STAT3 and stimulates proliferative ERK1/2 signaling. Systemic SHP2 inhibition in mice bearing tumors selected for SHP2-independent tumor-cell growth, promotes degeneration of the tumor vasculature and blood extravasation; reduces tumor vascularity and blood perfusion; and increases tumor hypoxia and necrosis. Reduction of tumor growth ensues, independent of SHP2 targeting in the tumor cells, blocking immune checkpoints or recruiting anti-tumor macrophages. We also show that inhibiting the Angiopoietin/TIE2/AKT cascade magnifies the vascular and anti-tumor effects of SHP2 inhibition by blocking tumor endothelial AKT signaling, not a target of SHP2. Since the SHP2 and Ang2/TIE2 pathways are active in vascular endothelial cells of human melanoma and colon carcinoma, SHP2 inhibitors alone or with Ang2/Tie2 inhibitors hold promise to effectively target the tumor endothelium.

scholarly journals Translocation of protein tyrosine phosphatase Pez/PTPD2/PTP36 to the nucleus is associated with induction of cell proliferation

2000 ◽  
Vol 113 (17) ◽  
pp. 3117-3123 ◽  
Author(s):  
C. Wadham ◽  
J.R. Gamble ◽  
M.A. Vadas ◽  
Y. Khew-Goodall
Keyword(s):  
Cell Proliferation ◽  
Endothelial Cells ◽  
Nuclear Protein ◽  
Vascular Endothelial Cells ◽  
Tyrosine Phosphatase ◽  
Subcellular Localisation ◽  
Vascular Endothelial ◽  
Proliferating Cells ◽  
Wound Edge

Pez is a non-transmembrane tyrosine phosphatase with homology to the FERM (4.1, ezrin, radixin, moesin) family of proteins. The subcellular localisation of Pez in endothelial cells was found to be regulated by cell density and serum concentration. In confluent monolayers Pez was cytoplasmic, but in cells cultured at low density Pez was nuclear, suggesting that it is a nuclear protein in proliferating cells. This notion is supported by the loss of nuclear Pez when cells are serum-starved to induce quiescence, and the rapid return of Pez to the nucleus upon refeeding with serum to induce proliferation. Vascular endothelial cells normally exist as a quiescent confluent monolayer but become proliferative during angiogenesis or upon vascular injury. Using a ‘wound’ assay to mimic these events in vitro, Pez was found to be nuclear in the cells that had migrated and were proliferative at the ‘wound’ edge. TGFbeta, which inhibits cell proliferation but not migration, inhibited the translocation of Pez to the nucleus in the cells at the ‘wound’ edge, further strengthening the argument that Pez plays a role in the nucleus during cell proliferation. Together, the data presented indicate that Pez is a nuclear tyrosine phosphatase that may play a role in cell proliferation.

scholarly journals Regulation of vasculogenesis and angiogenesis by EphB/ephrin-B2 signaling between endothelial cells and surrounding mesenchymal cells

Blood ◽  
2002 ◽  
Vol 100 (4) ◽  
pp. 1326-1333 ◽  
Author(s):  
Yuichi Oike ◽  
Yasuhiro Ito ◽  
Koichi Hamada ◽  
Xiu-Qin Zhang ◽  
Keishi Miyata ◽  
...  
Keyword(s):  
Endothelial Cells ◽  
Tyrosine Kinases ◽  
Molecular Mechanisms ◽  
Neuronal Development ◽  
Receptor Tyrosine Kinases ◽  
Vascular Endothelial Cells ◽  
Mesenchymal Cells ◽  
Ephb Receptor ◽  
Vasculogenesis And Angiogenesis

Although the cellular and molecular mechanisms governing angiogenesis are only beginning to be understood, signaling through endothelial-restricted receptors, particularly receptor tyrosine kinases, has been shown to play a pivotal role in these events. Recent reports show that EphB receptor tyrosine kinases and their transmembrane-type ephrin-B2 ligands play essential roles in the embryonic vasculature. These studies suggest that cell-to-cell repellent effects due to bidirectional EphB/ephrin-B2 signaling may be crucial for vascular development, similar to the mechanism described for neuronal development. To test this hypothesis, we disrupted the precise expression pattern of EphB/ephrin-B2 in vivo by generating transgenic (CAGp-ephrin-B2 Tg) mice that express ephrin-B2 under the control of a ubiquitous and constitutive promoter, CMV enhancer-β-actin promoter-β-globin splicing acceptor (CAG). These mice displayed an abnormal segmental arrangement of intersomitic vessels, while such anomalies were not observed in Tie-2p-ephrin-B2 Tg mice in which ephrin-B2 was overexpressed in only vascular endothelial cells (ECs). This finding suggests that non-ECs expressing ephrin-B2 alter the migration of ECs expressing EphB receptors into the intersomitic region where ephrin-B2 expression is normally absent. CAGp-ephrin-B2 Tg mice show sudden death at neonatal stages from aortic dissecting aneurysms due to defective recruitment of vascular smooth muscle cells to the ascending aorta. EphB/ephrin-B2 signaling between endothelial cells and surrounding mesenchymal cells plays an essential role in vasculogenesis, angiogenesis, and vessel maturation.

scholarly journals Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate

2013 ◽  
Vol 304 (11) ◽  
pp. E1131-E1139 ◽  
Author(s):  
Alejandro S. Godoy ◽  
Ivy Chung ◽  
Viviana P. Montecinos ◽  
Ralph Buttyan ◽  
Candace S. Johnson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Vitamin D ◽  
Endothelial Cells ◽  
Tumor Growth ◽  
Vascular Function ◽  
Tumor Vasculature ◽  
Prostate Tumor ◽  
Antiangiogenic Agents ◽  
Vitamin D Receptors ◽  
Published Evidence

Forty years ago, Judah Folkman (Folkman. N Engl J Med 285: 1182–1186, 1971) proposed that tumor growth might be controlled by limiting formation of new blood vessels (angiogenesis) needed to supply a growing tumor with oxygen and nutrients. To this end, numerous “antiangiogenic” agents have been developed and tested for therapeutic efficacy in cancer patients, including prostate cancer (CaP) patients, with limited success. Despite the lack of clinical efficacy of lead anti-angiogenic therapeutics in CaP patients, recent published evidence continues to support the idea that prostate tumor vasculature provides a reasonable target for development of new therapeutics. Particularly relevant to antiangiogenic therapies targeted to the prostate is the observation that specific hormones can affect the survival and vascular function of prostate endothelial cells within normal and malignant prostate tissues. Here, we review the evidence demonstrating that both androgen(s) and vitamin D significantly impact the growth and survival of endothelial cells residing within prostate cancer and that systemic changes in circulating androgen or vitamin D drastically affect blood flow and vascularity of prostate tissue. Furthermore, recent evidence will be discussed about the expression of the receptors for both androgen and vitamin D in prostate endothelial cells that argues for direct effects of these hormone-activated receptors on the biology of endothelial cells. Based on this literature, we propose that prostate tumor vasculature represents an unexplored target for modulation of tumor growth. A better understanding of androgen and vitamin D effects on prostate endothelial cells will support development of more effective angiogenesis-targeting therapeutics for CaP patients.

Solanum nigrum Suppress Angiogenesis-Mediated Tumor Growth Through Inhibition of the AKT/mTOR Pathway

2016 ◽  
Vol 44 (06) ◽  
pp. 1273-1288 ◽  
Author(s):  
Mon-Yuan Yang ◽  
Chia-Hung Hung ◽  
Chun-Hua Chang ◽  
Tsui-Hwa Tseng ◽  
Chau-Jong Wang
Keyword(s):  
Endothelial Cells ◽  
Tumor Growth ◽  
Hepg2 Cells ◽  
Vascular Endothelial Cells ◽  
Chorioallantoic Membrane ◽  
Solanum Nigrum ◽  
Mtor Pathway ◽  
Anticancer Activities ◽  
Edible Plant ◽  
Solanum Nigrum L

Solanum nigrum L., an edible plant and local dish, has been assigned anticancer activities. However, the anticancer mechanisms of S. nigrum are poorly understood. Here, we investigated whether the water or polyphenol extracts of S. nigrum (SNWE or SNPE) could inhibit angiogenesis-mediated tumor growth. In nude mice bearing tumor xenografts, SNWE or SNPE significantly reduced the volume and weight of the tumors, and decreased the expression of CD31, a marker for angiogenesis. SNWE or SNPE was found to inhibit the VEGF-induced capillary structure formation of endothelial cells. The chicken egg chorioallantoic membrane (CAM) and matrigel plug assays showed further that SNWE or SNPE inhibited tumor angiogenesis. In human umbilical vascular endothelial cells (HUVECs), SNWE or SNPE suppressed the VEGF-induced activation of AKT and mTOR. Moreover, SNWE or SNPE inhibited the viability of human hepatoma HepG2 cells, and these effects were correlated with the extent of inhibition of the AKT/mTOR pathway. Taken together, our data imply that SNWE or SNPE downregulated the AKT/mTOR pathway in HUVECs and HepG2 cells, which lead to reduced tumor growth and angiogenesis.

scholarly journals Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth

Blood ◽  
2008 ◽  
Vol 112 (5) ◽  
pp. 1904-1911 ◽  
Author(s):  
Marta Segarra ◽  
Cassin Kimmel Williams ◽  
Maria de la Luz Sierra ◽  
Marcelino Bernardo ◽  
Peter J. McCormick ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Notch Signaling ◽  
Tumor Cells ◽  
Blood Perfusion ◽  
Vascular Endothelial ◽  
Tumor Vascularity ◽  
Over Expression ◽  
Tumor Neovascularization ◽  
Endothelial Growth Factor ◽  
Notch Activation

Abstract Gene targeting experiments have shown that Delta-like 4 (Dll4) is a vascular-specific Notch ligand critical to normal vascular development. Recent studies have demonstrated that inhibition of Dll4/Notch signaling in tumor-bearing mice resulted in excessive, yet nonproductive tumor neovascularization and unexpectedly reduced tumor growth. Because nonfunctional blood vessels have the potential to normalize, we explored the alternative approach of stimulating Notch signaling in the tumor vasculature to inhibit tumor growth. Here we show that retrovirus-induced over-expression of Dll4 in tumor cells activates Notch signaling in cocultured endothelial cells and limits vascular endothelial growth factor (VEGF)–induced endothelial cell growth. Tumors produced in mice by injection of human and murine tumor cells transduced with Dll4 were significantly smaller, less vascularized and more hypoxic than controls, and displayed evidence of Notch activation. In addition, tumor blood perfusion was reduced as documented by vascular imaging. These results demonstrate that Notch activation in the tumor microenvironment reduces tumor neovascularization and blood perfusion, and suggest that Dll4-induced Notch activation may represent an effective therapeutic approach for the treatment of solid tumors.

scholarly journals Axl Is Essential for in-vitro Angiogenesis Induced by Vitreous From Patients With Proliferative Diabetic Retinopathy

2021 ◽  
Vol 8 ◽  
Author(s):  
Wenyi Wu ◽  
Huizuo Xu ◽  
Zhishang Meng ◽  
Jianxi Zhu ◽  
Siqi Xiong ◽  
...  
Keyword(s):  
Endothelial Cells ◽  
Diabetic Retinopathy ◽  
Proliferative Diabetic Retinopathy ◽  
Tyrosine Kinases ◽  
Vascular Endothelial Cells ◽  
Specific Inhibitor ◽  
Cell Types ◽  
Specific Protein ◽  
Vascular Endothelial

Proliferative diabetic retinopathy (PDR), characterized mainly with abnormal epiretinal angiogenesis forming fibrovascular membranes (FVMs), threatens vision of people with diabetes; FVMs consist of extracellular matrix and a variety of cell types including vascular endothelial cells. Axl, one of receptor tyrosine kinases, can be activated indirectly by vascular endothelial growth factor-A (VEGF-A) via an intracellular route for promoting angiogenesis. In this study, we revealed that growth arrest-specific protein 6 (Gas6), a specific ligand of Axl, was elevated in vitreous from patients with PDR and that Axl was activated in FVMs from patients with PDR. In addition, we demonstrated that in cultured human retinal microvascular endothelial cells (HRECs), Axl inhibition via suppression of Axl expression with Clustered Regularly Interspaced Short Palindromic Repeats/ CRISPR-associated protein 9 or through inactivation with its specific inhibitor R428 blocked PDR vitreous-induced Akt activation and proliferation of HRECs. Furthermore, PDR vitreous-heightened migration and tube formation of HRECs were also blunted by restraining Axl. These results indicate that in the pathogenesis of PDR, Axl can be activated by Gas6 binding directly and by VEGF-A via an intracellular route indirectly, suggesting that Axl plays a pivotal role in the development of PDR and that Axl inhibition shows a bright promise for PDR therapy.

Vascular Endothelial Protein Tyrosine Phosphatase Regulates Endothelial Function

Physiology ◽  
2021 ◽  
Vol 36 (2) ◽  
pp. 84-93
Author(s):  
Dietmar Vestweber
Keyword(s):  
Endothelial Cells ◽  
Adhesion Molecule ◽  
Tumor Angiogenesis ◽  
Protein Tyrosine Phosphatase ◽  
Therapeutic Potential ◽  
Vascular Endothelial Cells ◽  
Tyrosine Phosphatase ◽  
Tyrosine Kinase Receptor ◽  
Vascular Endothelial ◽  
Protein Tyrosine

Vascular endothelial protein tyrosine phosphatase (VE-PTP) is a receptor-type PTP (RPTP), predominantly expressed in vascular endothelial cells. It regulates embryonic and tumor angiogenesis and controls vascular permeability and homeostasis in inflammation. Major substrates are the tyrosine kinase receptor Tie-2 and the adhesion molecule VE-cadherin. This review describes how VE-PTP controls vascular functions by its various substrates and the therapeutic potential of VE-PTP in various pathophysiological settings.

Sign in / Sign up

Export Citation Format

Share Document